---
title: "FTO's Role in Cancer: Immune Evasion and Therapeutic Resistance Insights"
id: "frontiers-in-immunology-15-reader-dependent-functional-duality-of-fto-a-context-switching-node-at-the"
canonical_url: "https://medichelpline.com/clinical-feed/frontiers-in-immunology-15-reader-dependent-functional-duality-of-fto-a-context-switching-node-at-the"
content_type: "clinical_feed_article"
specialty: "Infectious Disease"
source_name: "Frontiers in Immunology"
source_url: "https://www.frontiersin.org/articles/10.3389/fimmu.2026.1861781"
published_at: "2026-07-20T00:00:00.000Z"
evidence_level: "Journal Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# FTO's Role in Cancer: Immune Evasion and Therapeutic Resistance Insights
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/frontiers-in-immunology-15-reader-dependent-functional-duality-of-fto-a-context-switching-node-at-the
- **Specialty:** [Infectious Disease](https://medichelpline.com/clinical-feed/infectious-disease.md)
- **Primary Source:** Frontiers in Immunology
- **Source URL:** [Original Journal Publication](https://www.frontiersin.org/articles/10.3389/fimmu.2026.1861781)
- **Published At:** 2026-07-20T00:00:00.000Z
- **Evidence Rating:** Journal Feed
## Executive GIST (TL;DR)
- The **fat mass and obesity-associated protein (FTO)** functions as a significant epitranscriptomic regulator in cancer - FTO's biological output is dependent on tumor lineage, subcellular localization, and m6A reader activities - The review examines FTO's contributions to **immune exclusion**, metabolic reprogramming, and therapeutic resistance - FTO modulates **PD-L1 expression** and influences responses to various therapies including chemotherapy and immunotherapy - Emerging treatments targeting FTO, including inhibitors and **FTO-degraders**, are discussed alongside preclinical evidence - Challenges include the calibration of mechanistic claims and translating findings into clinical trial designs by leveraging biomarker stratification
## Clinical Analysis & Structured Key Points
About us All journals All articles Submit your research Search Frontiers in Immunology Sections Articles Research Topics Editorial board About journal Published in Frontiers in Immunology Cancer Immunity and Immunotherapy 7 impact factor 11.3 citescore Part of a Research Topic Unraveling Cancer Epigenetics: From Mechanistic Pathways to Therapeutic Innovations Submission open 11k views 3 articles Editor & Reviewers Edited by X L Xinyu Ling Reviewed by Y Z Youran Zhang H W Hanling Wang Outline Abstract 1 Introduction 2 FTO in cancer: a concise biological primer 3 FTO as an architect of the tumor immune contexture 4 FTO and immune checkpoint blockade 5 FTO and therapeutic resistance 6 The convergence framework: shared molecular nodes 7 Pharmacological targeting of FTO 8 Critical appraisal: contradictions, caveats, and reproducibility 9 A roadmap forward: testable predictions 10 Conclusion Author contributions Funding Conflict of interest Generative AI statement Publisher’s note References Figures and Tables Figure 1 View in article Figure 2 View in article Figure 3 View in article Figure 4 View in article Figure 5 View in article Table 1 Cross-tumor landscape of FTO function in cancer. View in article Table 2 Role of FTO in tumor immune evasion and antitumor immunity: mechanistic, pharmacologic, and correlative evidence with cross-study synthesis. View in article Table 3 FTO in tumor immune evasion and antitumor immunity: mechanistic, pharmacological, and clinical evidence across cancer types. View in article Table 4 Role of FTO in Therapy Response and Resistance Across Cancer Types: Chemotherapy, Targeted Therapy, Radiotherapy, and Intercellular Transmission. View in article REVIEW article Front. Immunol., 20 July 2026 Sec. Cancer Immunity and Immunotherapy Volume 17 - 2026 | https://doi.org/10.3389/fimmu.2026.1861781 Reader-dependent functional duality of FTO: a context-switching node at the intersection of immune evasion and therapeutic resistance W T WenJie Tian 1 B X Bin Xie 2 P Z Peng Zhan 1* 1. Department of Urology, the Second Hospital of Jilin University, Changchun, China 2. Department of Biliary Surgery, Cancer Hospital of Dalian University of Technology, Cancer Hospital of China Medical University, Liaoning Cancer Hospital& Institute, Shenyang, Liaonin, China Abstract The fat mass and obesity-associated protein (FTO), an RNA demethylase acting on both internal m6;A and cap-proximal m6;Am, functions in cancer as a context-dependent epitranscriptomic regulator whose net effect cannot be reduced to an oncogene–tumor-suppressor dichotomy. Its biological output is shaped by tumor lineage, subcellular localization, upstream signaling, and competing m6;A reader activities, predominantly YTHDF2-mediated decay and IGF2BP-mediated stabilization, although both reader families display additional non-canonical functions and are themselves modulated by post-translational modifications. Building on the now well-established context-dependence of FTO biology, which we do not claim as a novel observation, this review synthesizes current evidence on FTO’s roles at the intersection of tumor immune contexture, immune checkpoint regulation, metabolic reprogramming, and therapeutic resistance. We examine how FTO may contribute to immune exclusion through metabolic competition, exosomal signaling, and stromal reprogramming; modulate PD-L1 expression through direct and indirect mechanisms; and influence response to chemotherapy, targeted therapy, radiotherapy, and CNS-directed treatment. Emerging FTO inhibitors, FTO-degraders, and combination strategies with immune checkpoint blockade, ferroptosis inducers, or glycolytic inhibitors are evaluated against their underlying preclinical evidence base. The contribution of this review lies less in proposing a new framework than in three forms of integration typically addressed in isolation: explicit calibration of mechanistic claims to evidence tier, systematic separation of tumor-intrinsic from immune-cell-intrinsic FTO functions across lymphoid and myeloid compartments, and translation of reader-network biology into biomarker-stratified trial design. Technical limitations of epitranscriptomic methods are addressed as constraints on inference. To our knowledge, no FTO-targeted strategy has yet entered Phase I oncology evaluation; current combination rationales therefore remain preclinically supported rather than clinically established. 1 Introduction Cancer remains a leading cause of mortality worldwide, and despite major advances in targeted therapies and immunotherapy, durable clinical responses are still limited by tumor heterogeneity, adaptive plasticity, and therapeutic resistance (1–4). Accordingly, the discovery of new therapeutic vulnerabilities and a deeper mechanistic understanding of tumor initiation and progression remain essential for advancing both early detection and effective treatment. In this context, RNA modifications have recently emerged as a major area of interest in cancer biology (5–7). RNA modifications comprise a diverse set of chemical alterations affecting RNA nucleotides, with broad consequences for RNA conformation and function. To date, more than 170 distinct RNA modifications have been described across virtually all classes of RNA molecules (8). These epitranscriptomic marks regulate multiple aspects of RNA biology, including splicing, stability, subcellular localization, translation, and RNA–RNA as well as RNA–protein interactions, thereby shaping a wide range of cellular processes (9–11). Among the enzymes involved in this regulatory landscape, FTO was the first m6A demethylase to be identified and is now recognized as a key modulator of N6-methyladenosine (m6A) dynamics in mRNA (12). Beyond its function in m6A demethylation, FTO has also been implicated in regulating m6A and m6Am modifications in snRNA, as well as m1A demethylation in tRNA (13). Available evidence suggests that FTO preferentially acts on m6A sites within nuclear polyadenylated RNA, whereas in the cytoplasmic compartment it can also remove methyl groups from mRNA, with a notable preference for the cap-adjacent m6Am modification (13). As a reversible and highly dynamic epitranscriptomic mark, m6A has been implicated in fundamental biological processes, including the control of gene expression, RNA turnover, and cell fate decisions (14). In the context of malignancy, FTO reshapes m6A patterns on selected transcripts, thereby contributing to tumor progression through the regulation of cellular aggressiveness, metastatic capacity, therapeutic resistance, and immune escape (15–21). FTO has emerged as a context-dependent epitranscriptomic regulator in cancer, influencing tumor progression, immune evasion, and therapeutic resistance in a manner that cannot be reduced to a simple oncogene–tumor suppressor dichotomy (22–25). Of particular relevance, its function is context-dependent: in hepatocellular carcinoma and bladder cancer, both oncogenic and tumor-suppressive roles have been reported (26–32), while in prostate and colorectal cancer FTO can either restrain or promote malignancy depending on the transcript context and downstream signaling output (33–37). These observations suggest that FTO functions as a context-switching regulatory node rather than a linear cancer driver (22–25). Mechanistically, the net biological consequence of FTO-mediated demethylation appears to depend on tumor lineage, target-transcript selection, and the balance of competing m6A readers, particularly YTHDF2- and IGF2BP2-dependent pathways (17, 38, 39). However, the field still lacks an integrated framework that explains and predicts why the same demethylase produces opposite biological outcomes across cancers. Moreover, most available evidence remains largely preclinical, underscoring the need for reader-network-based and lineage-aware models to guide translational targeting of FTO (17, 34, 35, 38, 39). This review begins with a concise synthesis of FTO’s biological functions and its pivotal role in RNA epitranscriptomic regulation, before delineating the tumor-type-specific landscape of its activity and dissecting how it reshapes the tumor immune contexture through metabolic competition, immune checkpoint modulation, and remodeling of lymphoid and myeloid compartments. We subsequently integrate current evidence implicating FTO in resistance to chemotherapy, targeted therapy, radiotherapy, and immunotherapy, with a particular focus on the shared molecular nodes that mechanistically couple immune evasion to treatment failure. We then survey emerging pharmacological strategies against FTO and revisit the reader-dependent organizing logic that has emerged from recent literature, with particular attention to dimensions that remain underdeveloped in current syntheses: explicit evidence-tier calibration, the post-translational regulation of m6;A reader function itself, and the translation of reader-network biology into biomarker-stratified clinical trial design. By integrating these dimensions, this review aims to address an integration gap in the literature and to consider how context-aware, biomarker-guided targeting of FTO may contribute to more selective therapeutic approaches. 2 FTO in cancer: a concise biological primer 2.1 The FTO paradox and core molecular functions A note on evidence calibration. The mechanistic evidence underlying current understanding of FTO in cancer is heterogeneous in its experimental rigor, and uncritical aggregation across evidence tiers can produce false-precision conclusions. Throughout this review, we have therefore attempted to calibrate every mechanistic claim to its underlying evidence base, distinguishing among five tiers: (i) mechanisms validated by genetic perturbation in multiple in vivo models with concordant patient-sample correlations; (ii) mechanisms supported by single in vivo perturbation studies (typically syngeneic or xenograft) with mechanistic supporting evidence; (iii) mechanisms demonstrated in vitro across multiple cell lines, awaiting in vivo confirmation; (iv) mechanisms reported in single cell-line or single-model experiments that establish a candidate axis but cannot, in isolation, support generalization; and (v) correlative associations derived from bulk transcriptomic, single-cell, or spatial profiling that identify candidate relationships but cannot establish causation. Where claims rest predominantly on tier (iv) or (v) evidence, we have explicitly indicated this limitation in the surrounding text rather than relegating it to a generic acknowledgment, and we have replaced framings such as “establishes,” “demonstrates,” and “orchestrates” with calibrated alternatives (“supports,” “indicates,” “is consistent with”) when the evidence does not justify the stronger claim. This approach is intended to preserve the conceptual integration that motivates a synthetic review while preventing the systematic upgrade of single-system findings into generalized biology, a pattern that has, in our view, frequently characterized the FTO literature itself. FTO, identified as the first RNA demethylase shown to erase m6A in nuclear RNA (40), has since emerged as a regulator whose behavior in cancer does not conform to a simple oncogene-versus-tumor-suppressor dichotomy. Across the oncological landscape, FTO has been alternately implicated as a driver of leukemogenesis, melanoma progression and breast tumor aggressiveness, yet as a restraint on stem-like properties in colorectal carcinoma and on transformation in several other solid-tumor lineages (22–25). This “FTO paradox” is increasingly understood not as a literature-wide inconsistency but as the predictable output of a regulatory node whose net effect is dictated by converging contextual variables: the preferred substrate engaged (internal m6A versus cap-adjacent m6Am, often associated with cytoplasmic localization and displaying distinct transcript selectivity) (13, 25, 41), the subcellular compartment in which catalytic activity is executed, the lineage-specific transcriptomic landscape on which it operates, and the co-occurring activity of m6A writers and reader proteins that translate mark erasure into divergent downstream outputs (42). Collectively, emerging evidence suggests that this paradox likely reflects both biological context and methodological heterogeneity, whether studies interrogate bulk m6;A changes, cap-proximal m6;Am dynamics, or transcript-resolved stability and translation outputs, rather than a genuine biological ambiguity in FTO function. In contrast to the framing of FTO as a linear effector of m6A-dependent oncogenesis, a more coherent model positions it as a context-integrating node whose outputs are constrained by the chemical, spatial and cellular state in which it operates. Layered onto this substrate- and compartment-level regulation is a post-translational architecture that tunes FTO activity in a context-dependent manner. Acetylation at conserved lysine residues — most notably K88, mediated by the acetyltransferase GCN5, enhances RNA engagement and demethylase activity without perturbing FTO stability, localization, or dimerization, and is elevated across several malignancies, providing a potential mechanistic link between nutrient and metabolic cues and epitranscriptomic rewiring (43). Ubiquitin-dependent turnover and incompletely mapped phosphorylation events further position FTO as a sensor of proteostatic and oxidative stress cues (44). A preprint study (awaiting peer review) additionally reports FTO localization to centrosomes, where it may support NuMA- and KIFC1-dependent spindle organization (45), if confirmed, this would extend FTO’s role beyond cap chemistry to the maintenance of mitotic fidelity in chromosomally unstable tumors. The integrated functional outputs of this node therefore span cancer-stem-cell reprogramming, metabolic rewiring of glycolytic and lipid-handling circuits, adaptive stress responses and genome-stability control, with the dominant output in any given tumor determined by which inputs prevail. Substantial knowledge gaps nonetheless persist: current methodologies do not always resolve the relative contributions of internal m6A and cap-adjacent m6Am, and they provide only limited spatial resolution of the nuclear and cytoplasmic pools through which FTO exerts substrate-selective effects (13). It is precisely this context dependence, rather than any unified pro- or anti-tumor identity, that predicts FTO’s divergent influence on the tumor-immune microenvironment and on sensitivity to immune-checkpoint blockade and targeted therapy (23, 46), a theme developed in the sections that follow. 2.2 The tumor-type landscape Across the studies compiled in Table 1, encompassing gastrointestinal, hepatobiliary, genitourinary, breast and gynecological, lung, head-and-neck, central nervous system, pancreatic, hematological and other malignancies, FTO emerges not as a uniformly oncogenic or tumor-suppressive enzyme but as a context-dependent regulator whose net direction is dictated by tissue lineage and cellular state. A predominantly oncogenic profile has been reported in gastric, cervical, oesophageal squamous, ovarian, pancreatic ductal, nasopharyngeal and renal-cell carcinomas and in T-cell acute lymphoblastic leukemia, where elevated FTO supports proliferation, invasion, lymph-node dissemination and stem-like reprogramming (47–65). In contrast, FTO has been reported to function as a tumor suppressor in prostate carcinoma, papillary thyroid carcinoma, lung adenocarcinoma, glioma, multiple myeloma and osteosarcoma, and within the Epstein–Barr-virus-associated subtype of gastric cancer, where its loss accelerates growth, epithelial–mesenchymal transition and metastasis (66–76). Hepatocellular, bladder, breast and colorectal carcinomas occupy a third, internally inconsistent category in which both oncogenic and tumor-suppressive functions have been reported within the same tissue, sometimes with opposing prognostic correlations (26–32, 38, 39, 77–82). This distribution is unlikely to reflect experimental noise alone; rather, it may reflect the convergence of a shared catalytic activity onto distinct transcriptomic landscapes, reader-protein repertoires and upstream signals that sculpt FTO abundance and activity in each context. Table 1 Cancer type FTO level Role Direct m6A/m6Am target(s) Reader/mediator Pathway/process Functional output Ref. Colon cancer ↑ Onc PKM2 — Glycolysis (Warburg) Proliferation, invasion, metastasis (54) CRC ↑ Onc ZNF687 — Wnt/β-catenin Proliferation, invasion, migration, angiogenesis (77) CRC ↑ Regulatory KCTD15 (anti-tumor) YTHDF2 p53/HDAC1 axis FTO stabilizes KCTD15 → ↓proliferation, ↑apoptosis (34) CRC ↓ TS (cohort) HK2 IGF2BP2 FOXO/glycolysis (with ALKBH5) ↑Glycolysis, proliferation when FTO/ALKBH5 lost (39) CRC ↑ (USP30) Onc PHGDH, PSAT1 YTHDF2 Serine biosynthesis USP30 stabilizes FTO → tumor growth (82) Gastric ↑ Onc CCL2 YTHDF2 (antag.) Autophagy ↓, ROS ↓ Proliferation, survival, tumor growth (55) Gastric ↑ Onc MAP4K4 — — Proliferation, migration, invasion, ↓apoptosis (56) EBVaGC ↑ (MYC) TS FOS IGF2BP1/2 — Suppresses metastasis, invasiveness (66) Gastric ↑ Onc GLG1 — mRNA stability Migration, invasion, metastasis (173) Gastric ↑ Onc SP1, AURKB — ATM/p38 ↑, p53 ↓ Tumorigenesis, viability, colony, migration, invasion (174) Gastric (CagA+) ↑ (CagA→Jun) Onc HBEGF — EMT (hit-and-run) Metastasis; persists after H. pylori eradication (47) Gastric ↑ Onc circFAM192A → SLC7A5 — Leucine uptake, mTOR Proliferation (48) Gastric ↑ Onc SOX2 — Stemness Tumor growth, stem-cell properties (49) Gastric ↑ Onc FSP1 YTHDF2 Ferroptosis suppression Proliferation, migration; AS-IV ↓FTO → ferroptosis (85) HCC ↑ Onc BUB1 YTHDF2 TGF-β/TGF-βR1 Proliferation, invasion, EMT (26) HCC ↓ TS VEGFA — Angiogenesis FTO loss → growth, metastasis (27) HCC ↓ (nuclear) TS — — — Reduced nuclear FTO → poor prognosis (clinical) (28) HCC ↓ TS circGPR137B (feedback loop) — — Suppresses tumorigenesis, invasion, lung mets (29) HCC ↑ (lncRNA FTO-IT1) Onc GLUT1, PKM2, c-Myc YTHDF2 (antag.) Glycolysis (c-Myc loop) Proliferation, glycolysis (53) Bladder ↑ Onc STAT3 — STAT3 signalling Proliferation, migration (30) Bladder ↓ TS MALAT1, NOTCH1, CSNK2A2, ITGA6 SFPQ 5′/3′ UTR m6A modulation ↓Proliferation, ↓invasion, ↑apoptosis (31) Bladder ↓ TS EMG1 — Ribosome biogenesis ↓Proliferation, migration, invasion (32) Prostate ↓ TS miR-139-5p (stab.) → ZNF217 — PI3K/Akt/mTOR ↓ ↓Proliferation, EMT, lung metastasis (67) Prostate ↓ in EMT TS/EMT mod. DDIT4 IGF2BP2/3 EMT FTO loss → ↑motility, invasion, EMT (33) CRPC ↓ (DNA-damage Ub) TS FOXO3a — — FTO loss → growth; FTO ↑ enhances PARPi response (68) Prostate ↑ (with ZFHX3 loss) Onc context E2F2, CDKN2C — Proliferation ZFHX3 loss → ↑FTO activity → ↑growth (37) Prostate ↓ TS CLIC4 — mRNA stability FTO loss → ↑proliferation, metastasis (69) Prostate ↓ TS EGR2 — Cell cycle, growth pathways FTO ↑ → ↓proliferation, migration, invasion (36) ccRCC ↑ Onc SLC1A5 — Glutamine metabolism, reductive carbox., pyrimidines ↑Growth, survival; FTO inhibition → ↑ROS, DNA damage (50) Breast ↑ Onc CYP27B1 HNRNPC Vit-D ↓ → STAT3 ↑ (positive loop) Tumor growth, chemoresistance (78) TNBC ↑ Onc NFKBIE — NF-κB-related Proliferation, migration, invasion (79) Breast ↑ Onc lncRNA GAS5 (destab.) IGF2BP2 QKI pathway ↑Proliferation (GAS5 normally tumor-suppressive) (38) Breast (HER2+) ↑ Onc miR-181b-3p ↓ → ARL5B ↑ — — Migration, invasion (80) TNBC (metastatic) Activated by uncouplers/2-HG ↓ TS (when active) SHMT2, MTHFD2, MTHFD1L — Mitochondrial serine catabolism (MSCP) FTO activation → ↓MSCP, ↓lung metastasis (81) Cervical ↑ Onc FGF2 — Lactate, growth Proliferation, ↓apoptosis (51) Cervical ↑ Onc ZEB1, Myc — EMT/proliferation Proliferation, migration, invasion (52) Cervical ↑ Onc PIK3R3 — FoxO pathway Proliferat
## Related Clinical Research

- [BANF1, Genome Stability, and Innate Immunity: Implications for Hematologic Malignancies](https://medichelpline.com/clinical-feed/frontiers-in-immunology-15-banf1-at-the-crossroads-of-genome-stability-and-innate-immunity-emerging.md)
- [Arginine supplements and immune recognition: mouse study links arginine to improved cancer and vir](https://medichelpline.com/clinical-feed/medical-news-today-0-could-arginine-supplements-help-boost-immune-responses-to-cancer-viruses.md)
- [Obesity-associated inflammation and cancer: mechanisms linking adipose immune changes to tumor risk](https://medichelpline.com/clinical-feed/frontiers-in-immunology-6-obesity-associated-inflammation-and-cancer-molecular-mechanisms-evidence-gaps.md)
- [CBC-derived inflammatory indices in colorectal cancer: diagnostic and prognostic head-to-head anal](https://medichelpline.com/clinical-feed/british-journal-of-cancer-0-complete-blood-count-derived-inflammation-indices-in-colorectal-cancer-head-to.md)
- [HUSH complex in retrotransposon silencing and its implications for cancer](https://medichelpline.com/clinical-feed/pubmed-42848310.md) (DOI: 10.1007/s12032-026-03380-w)

## Navigation
- [← Back to Infectious Disease Feed](https://medichelpline.com/clinical-feed/infectious-disease.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.